Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type.
The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.
Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to pioneer a new class of in vivo reprogramming therapies and transform the development of ex vivo cell therapies for indications of high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.
Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, as well as the exploration and generation of novel in vivo reprogramming and cell-based therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
Location: United Kingdom, Cambridge
Funding Rounds 4
|04.05.2021||Series A||$33M||Parkwalk A...||-|
Mentions in press and media 36